Takeda

Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.

HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.

The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.

The Avatar Research Program will collect de-identified genomic and clinical information from consenting patients treated at ORIEN cancer centers.

The partners will screen for molecules that could revive metabolic activity in heart tissue damaged by cardiovascular disease or failure.

NEW YORK (GenomeWeb) – Using a new in-phase assay, researchers led by Duke University's Allen Roses believe they have captured key differences in APOE and TOMM40 haplotypes between African-American, Caucasian, and West African populations.

Seattle Genetics will receive a $6 million milestone payment from Takeda Pharmaceutical after the first commercial sales of Adcetris in Australia, South Korea, and Mexico.

This is the first of a two-part feature on the state of personalized drug development. The first part focuses on the scientific challenges facing the industry. The second part discusses the evolving regulatory and financial environment and recent advances in the field.

This article has been updated from a previous version to correct the pioglitazone dose to be used in the TOMMORROW trial. It is 0.8 mg/day, not 0.6 mg/day. Originally published Sept. 3.

Pages

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.